Welcome to our dedicated page for RVPHW SEC filings (Ticker: RVPHW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reviva Pharmaceuticals Holdings, Inc. filings document material-event disclosures for a public pharmaceutical operating company, including 8-K reports on operating and financial results, Regulation FD updates, material agreements, clinical or regulatory matters, capital-structure disclosures, and Nasdaq continued-listing compliance.
The records also cover security-holder rights, certificate or bylaw amendments, registered common stock information, security-structure disclosures, exhibits, press releases, and Inline XBRL cover-page data.
Reviva Pharmaceuticals Holdings is conducting a primary offering of 27,000,000 shares of common stock, together with Series E warrants for up to 27,000,000 shares and Series F warrants for up to 27,000,000 shares, at a combined public offering price of $0.335 per share and accompanying warrants, for maximum gross proceeds of $9,045,000. After placement fees and expenses, net proceeds are estimated at about $8.1 million, with the company planning to use the cash for research and development of its lead drug brilaroxazine and for working capital.
The offering is a best-efforts, no-minimum deal led by A.G.P., so Reviva may raise substantially less than the maximum and investor funds will not be placed in escrow. Common shares outstanding would be 96,337,119 after the transaction, before any warrant exercises, resulting in dilution for new and existing holders. The Series E warrants are exercisable immediately at $0.335 for five years, while the Series F warrants share the same exercise price with a 12‑month term.
Reviva highlights positive Phase 3 RECOVER-1 data and one‑year open‑label extension results in schizophrenia and plans to seek an FDA meeting in Q4‑2025 to discuss a potential NDA based on existing trials, with a possible NDA filing targeted for Q2‑2026 if the agency response is favorable and additional financing is secured.
Reviva Pharmaceuticals plans a primary offering of common stock, together with Series E and Series F common warrants, and pre-funded warrants sold in lieu of common stock for certain large investors. Each share or pre-funded warrant will be sold with one Series E warrant and one Series F warrant, both exercisable immediately, with the Series E warrant having a five-year term and the Series F warrant a 12‑month term. The transaction is a best‑efforts, no‑minimum offering led by A.G.P./Alliance Global Partners, so proceeds to Reviva will depend on actual investor demand.
Reviva expects to use net proceeds mainly to fund research and development for its lead drug brilaroxazine and for working capital and general corporate purposes. The prospectus highlights positive Phase 3 RECOVER-1 and one‑year open‑label extension results in schizophrenia and outlines a potential path to an NDA submission based on existing Phase 2 and Phase 3 data. The company cautions that investors may face dilution, that the warrants will not be listed, and that limited proceeds could constrain its ability to execute its business plan.